JPH11504668A - ヒアルロン酸との又はヒアルロン酸エステルとのコハク酸ヘミエステルの重金属塩類、それらの製造方法及びその医薬組成物 - Google Patents
ヒアルロン酸との又はヒアルロン酸エステルとのコハク酸ヘミエステルの重金属塩類、それらの製造方法及びその医薬組成物Info
- Publication number
- JPH11504668A JPH11504668A JP8533769A JP53376996A JPH11504668A JP H11504668 A JPH11504668 A JP H11504668A JP 8533769 A JP8533769 A JP 8533769A JP 53376996 A JP53376996 A JP 53376996A JP H11504668 A JPH11504668 A JP H11504668A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronic acid
- succinic
- hemiester
- acid
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 123
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 123
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 107
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 title claims abstract description 67
- 150000003839 salts Chemical class 0.000 title claims abstract description 63
- 229910001385 heavy metal Inorganic materials 0.000 title claims abstract description 35
- 239000001384 succinic acid Substances 0.000 title claims abstract description 33
- -1 hyaluronic acid ester Chemical class 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 7
- 150000002148 esters Chemical class 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 206010052428 Wound Diseases 0.000 claims abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 5
- 241001420836 Ophthalmitis Species 0.000 claims abstract description 4
- 208000010403 panophthalmitis Diseases 0.000 claims abstract description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- 150000001735 carboxylic acids Chemical group 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 59
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 46
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 24
- 239000010949 copper Substances 0.000 claims description 18
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 18
- 229910052709 silver Inorganic materials 0.000 claims description 18
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical group [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 17
- 239000004332 silver Substances 0.000 claims description 17
- 229910052802 copper Inorganic materials 0.000 claims description 15
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 14
- 229940014800 succinic anhydride Drugs 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 13
- 239000011701 zinc Substances 0.000 claims description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 12
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 239000010931 gold Chemical group 0.000 claims description 11
- 229910052725 zinc Inorganic materials 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052737 gold Inorganic materials 0.000 claims description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 150000001768 cations Chemical class 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 6
- 239000011541 reaction mixture Substances 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 150000007530 organic bases Chemical class 0.000 claims description 5
- 239000000010 aprotic solvent Substances 0.000 claims description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 4
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 239000012265 solid product Substances 0.000 claims description 4
- 125000005207 tetraalkylammonium group Chemical group 0.000 claims description 4
- KIUKXJAPPMFGSW-YXBJCWEESA-N (2s,4s,5r,6s)-6-[(2s,3r,5s,6r)-3-acetamido-2-[(3s,4r,5r,6r)-6-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@@H]3[C@@H]([C@@H](O)C(O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)C(C(O)=O)O1 KIUKXJAPPMFGSW-YXBJCWEESA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 125000005497 tetraalkylphosphonium group Chemical group 0.000 claims description 3
- 229910052721 tungsten Inorganic materials 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 239000012620 biological material Substances 0.000 claims description 2
- 239000003729 cation exchange resin Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- IYWCBYFJFZCCGV-UHFFFAOYSA-N formamide;hydrate Chemical compound O.NC=O IYWCBYFJFZCCGV-UHFFFAOYSA-N 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 150000004714 phosphonium salts Chemical class 0.000 claims 1
- 239000010944 silver (metal) Substances 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- 239000003899 bactericide agent Substances 0.000 abstract description 2
- 239000012153 distilled water Substances 0.000 description 27
- 229920000642 polymer Polymers 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 229920002385 Sodium hyaluronate Polymers 0.000 description 7
- 229940010747 sodium hyaluronate Drugs 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000003456 ion exchange resin Substances 0.000 description 6
- 229920003303 ion-exchange polymer Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 229940014041 hyaluronate Drugs 0.000 description 5
- 229910001923 silver oxide Inorganic materials 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 150000003751 zinc Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000001879 copper Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 3
- 230000035322 succinylation Effects 0.000 description 3
- 238000010613 succinylation reaction Methods 0.000 description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910052684 Cerium Inorganic materials 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 150000003890 succinate salts Chemical class 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 2
- 239000010937 tungsten Substances 0.000 description 2
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910021612 Silver iodide Inorganic materials 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 229940100890 silver compound Drugs 0.000 description 1
- 150000003379 silver compounds Chemical class 0.000 description 1
- 229940096017 silver fluoride Drugs 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- REYHXKZHIMGNSE-UHFFFAOYSA-M silver monofluoride Chemical compound [F-].[Ag+] REYHXKZHIMGNSE-UHFFFAOYSA-M 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- LMEWRZSPCQHBOB-UHFFFAOYSA-M silver;2-hydroxypropanoate Chemical compound [Ag+].CC(O)C([O-])=O LMEWRZSPCQHBOB-UHFFFAOYSA-M 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003443 succinic acid derivatives Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下の繰り返しユニット(I)を有する、ヒアルロン酸との又はヒアルロン 酸の部分若しくは全エステルとのコハク酸ヘミエステル: (式中、R1、R2及びR3は、それぞれ同一でも異なっていてもよく、H又は CO(CH2)2−COOYであり、その式中、Yは、陰電荷又はHであり、Rは 、OH、O-又はアルコール残部である)。 2.繰り返しユニット(I)において、R1=R2=R3=Hである請求項1に記 載のコハク酸ヘミエステル。 3.少なくとも1種の繰り返しユニット(I)(R1=R3=Hであり、R2=C O(CH2)2−COOYである)、及び少なくとも1種の繰り返しユニット(I )(R2=R3=Hであり、R1=CO(CH2)2−COOYである)を有する請 求項1に記載のコハク酸ヘミエステル。 4.以下の繰り返しユニット(II)を有する、ヒアルロン酸との又はヒアルロン 酸の部分若しくは全エステルとのコハク酸ヘミエステルの重金属塩: (式中、R1、R2及びR3は、それぞれ同一でも異なっていてもよく、H又は CO(CH2)2−COO-であり、Rは、O-又はアルコール残部であり、(XZ+ )は、重金属のカチオン(Zは1〜6である)であり、pは、0.1〜5の整数又 は少数であり、但し、p(XZ+)は、該繰り返しユニット中に存在するアニオン 基COO-の数と等しい)。 5.XがAg、Cu、Zn、Au、Ce、Wからなる群から選択された請求項4 に記載の重金属塩。 6.R1=R2=R3=Hであり、Xが銀、金、銅、亜鉛からなる群から選択され 、Zが1〜3の整数であり、pが0.3〜2からなる請求項4又は5に記載の重金 属塩。 7.少なくとも1種の繰り返しユニット(II)(R1=R3=Hであり、R2=C O(CH2)2−COO-である)、及び少なくとも1種の繰り返しユニット(II )(R2=R3=Hであり、R1=CO(CH2)2−COO-である)を有し、Xが 銀、金、銅、亜鉛からなる群から選択され、Zが1〜3であり、pが0.6〜3か らなる請求項4、5又は6のいずれか1項に記載の重金属塩。 8.以下の工程を含む請求項4、5、6又は7のいずれか1項に記載の、ヒアル ロン酸との又はヒアルロン酸の部分又は全エステルとのコハク酸ヘミエステルの 重金属塩の製造方法: a)ヒアルロン酸ナトリウム塩を、水及び非プロトン性溶媒の存在下で、ピリ ジニウム、テトラアルキルアンモニウム、テトラアリールアンモニウム、テトラ アルキルホスホニウム、テトラアリールホスホニウム塩からなる群から選択され た塩に転化すること、 b)工程(a)で得た溶液を、触媒としての有機塩基の存在下においてコハク酸 無水物を用いて処理し、ピリジニウム、テトラアルキルアンモニウム、テトラア リールアンモニウム、テトラアルキルホスホニウム、又はテトラアリールホスホ ニウムカチオンを透析により除去し、それにより、少なくとも1種の繰り返しユ ニット(I)(式中、R1、R2及びR3はそれぞれ同一でも異なっていてもよく 、H又はCO(CH2)2−COOYであり、その式中、Yは、陰電荷又はHであ り、Rは、OH、O-又はアルコール残部であり、但し、1種の繰り返しユニッ ト(I)においては、少なくとも、RがOH又はO-である)を有する、ヒアル ロン酸との又はそれらの部分エステルとのコハク酸ヘミエステルを得ること、及 び任意に、得られた生成物を凍結乾燥により回収すること、 c)前述の工程で得た溶液、又は前述の工程で得た回収固形生成物の水溶液を 重金属の無機塩の水溶液で処理し、濾過及び減圧乾燥により生成物を回収するこ と。 9.工程(a)において、ヒアルロン酸を、以下の作業条件を用いることにより 、そのピリジニウム塩に添加する請求項8に記載の方法: i)水及びジメチルホルムアミドの混合物中において、ヒアルロネートナトリ ウム塩を溶解させること、 ii)カチオン交換樹脂で処理して、その遊離ヒアルロン酸を得ること、 iii)反応混合物をピリジンにより中和し、それにより、ピリジニウム塩を得 ること。 10.以下の工程を含む、ヒアルロン酸の全エステルとのコハク酸ヘミエステルの 重金属塩を製造する方法: b')水及び非プロトン性溶媒の混合物中に溶解又は懸濁されたヒアルロン酸 エステルを、有機塩基の存在下においてコハク酸無水物を用いて処理し、それに より、以下の繰り返しユニット(I)を有するコハク酸ヘミエステルを得ること 、及び任意に、得られた生成物を凍結乾燥により回収すること: (式中、Rは、アルコールの残部である) c)前述の工程で得た溶液、又は前述の工程で得た回収固形生成物の水溶液を 重金属の無機塩の水溶液で処理し、濾過及び減圧乾燥により生成物を回収するこ と。 11.工程(b)又は(b')を、以下の出発材料ヒアルロン酸又はヒアルロン酸の 部分エステルの繰り返しユニット(III)におけるコハク酸無水物/遊離OH基 のモル比を15〜90とし、70℃で行い、その触媒を、4−ジメチルアミノピリジン 、ピリジン又はそれらの混合物からなる群から選択する請求項8、9又は10のい ずれか1項に記載の方法: 12.ヒアルロン酸又はヒアルロン酸エステルとのコハク酸ヘミエステルのAg塩 を製造するための、請求項8、9、10又は11のいずれか1項に記載の方法であっ て、工程(c)又は(c')において、ヒアルロン酸とのコハク酸ヘミエステル又 はヒアルロン酸の部分又は全エステルとのコハク酸ヘミエステルを、硝酸銀の水 溶液で処理する該方法。 13.ヒアルロン酸との又はヒアルロン酸エステルとのコハク酸ヘミエステルのZ n塩を製造するための、請求項8、9、10又は11のいずれか1項に記載の方法であ って、工程(c)又は(c')において、ヒアルロン酸との又はヒアルロン酸の部 分又は全エステルとのコハク酸ヘミエステルを、ZnCl2で処理する該方法。 14.ヒアルロン酸又はヒアルロン酸エステルとのコハク酸ヘミエステルのCu塩 を製造するための、請求項8、9、10又は11のいずれか1項に記載の方法であっ て、工程(c)又は(c')において、ヒアルロン酸とのコハク酸ヘミエステル又 はヒアルロン酸エステルとのコハク酸ヘミエステルを、CuCl2の水溶液で処 理する該方法。 15.ヒアルロン酸又はヒアルロン酸エステルとのコハク酸ヘミエステルのAu塩 を製造するための、請求項8、9、10又は11のいずれか1項に記載の方法であっ て、工程(c)又は(c')において、ヒアルロン酸とのコハク酸ヘミエステル又 はヒアルロン酸エステルとのコハク酸ヘミエステルを、HAuCl4の水溶液で 処理する該方法。 16.活性成分として、請求項4、5、6又は7のいずれか1項に記載のヒアルロ ン酸との又はヒアルロン酸の部分又は全エステルとのコハク酸ヘミエステルの重 金属塩を少なくとも1種、及び任意に、他の同様の治療作用を有する活性成分を 含む治療組成物。 17.火傷、傷及び眼炎の治療用の、請求項16に記載の治療組成物。 18.軟膏、クリームジェルの形態である請求項16又は17に記載の治療組成物。 19.活性成分として、ヒアルロン酸又はヒアルロン酸の部分又は全エステルとの コハク酸ヘミエステルのAg塩を含む請求項16、17又は18に記載の治療組成物。 20.骨関節炎の治療用の、請求項16に記載の治療組成物。 21.活性成分として、ヒアルロン酸との又はヒアルロン酸エステルとのコハク酸 ヘミエステルの重金属塩少なくとも1種であって、Au、Cu及びZn又はそれ らの混合物の塩からなる群から選択された塩を含む請求項16又は20に記載の治療 組成物。 22.請求項4、5、6又は7のいずれか1項に記載のヒアルロン酸又はヒアルロ ン酸エステルとのコハク酸ヘミエステルの重金属塩を少なくとも1種を含むヘル スケア組成物。 23.請求項4、5、6又は7のいずれか1項に記載の重金属塩を少なくとも1種 含む生体材料。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT95PD000090A IT1281877B1 (it) | 1995-05-10 | 1995-05-10 | Sali di metalli pesanti di succinil derivati dell'acido ialuronico e loro impiego come potenziali agenti terapeutici |
IT95A000090 | 1995-08-18 | ||
PCT/EP1996/001979 WO1996035720A1 (en) | 1995-05-10 | 1996-05-08 | Heavy metal salts of succinic acid hemiesters with hyaluronic acid, or hyaluronic acid esters, a process for their preparation, and relative pharmaceutical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11504668A true JPH11504668A (ja) | 1999-04-27 |
JP4264671B2 JP4264671B2 (ja) | 2009-05-20 |
Family
ID=11391041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53376996A Expired - Fee Related JP4264671B2 (ja) | 1995-05-10 | 1996-05-08 | ヒアルロン酸との又はヒアルロン酸エステルとのコハク酸ヘミエステルの重金属塩類、それらの製造方法及びその医薬組成物 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0827514B1 (ja) |
JP (1) | JP4264671B2 (ja) |
AT (1) | ATE183206T1 (ja) |
AU (1) | AU695512B2 (ja) |
CA (1) | CA2220682C (ja) |
DE (1) | DE69603721T2 (ja) |
ES (1) | ES2137694T3 (ja) |
IT (1) | IT1281877B1 (ja) |
WO (1) | WO1996035720A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009510186A (ja) * | 2005-09-26 | 2009-03-12 | ノボザイムス バイオポリマー アクティーゼルスカブ | アリール/アルキル無水琥珀酸ヒアルロナン誘導体 |
JP2014500257A (ja) * | 2010-11-19 | 2014-01-09 | フィディア ファーマチェウティチ ソシエタ ペル アチオニ | 抗菌および創傷治癒活性を持つ組成物 |
JP2018510962A (ja) * | 2015-04-07 | 2018-04-19 | ヒャルブルー エス.アール.エル. | グリコサミノグリカンエステル、それらを調製する方法および眼科用途のための製剤におけるそれらの使用 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0781566B1 (en) * | 1995-12-26 | 2004-07-28 | Toyo Boseki Kabushiki Kaisha | Organic solvent-soluble mucopolysaccharide, antibacterial antithrombogenic composition and medical material |
IT1291452B1 (it) | 1997-04-14 | 1999-01-11 | Fidia Advanced Biopolymers Srl | Rivestimento a base di acido ialuronico e suoi derivati per la protezione di parti elettroniche da agenti esterni |
IT1294797B1 (it) * | 1997-07-28 | 1999-04-15 | Fidia Advanced Biopolymers Srl | Uso dei derivati dell'acido ialuronico nella preparazione di biomateriali aventi attivita' emostatica fisica e tamponante |
US6872819B1 (en) * | 1998-05-27 | 2005-03-29 | Fidia Advanced Biopolymers S.R.L. | Biomaterials containing hyaluronic acid derivatives in the form of three-dimensional structures free from cellular components or products thereof for the in vivo regeneration of tissue cells |
ITPD980149A1 (it) | 1998-06-17 | 1999-12-17 | Fidia Advanced Biopolymers Srl | Protesi tridimensionali comprendenti derivati dell'acido ialuronico per riparare o ricostruire i tessuti danneggiati e processo per la |
JP2003089647A (ja) * | 1999-03-10 | 2003-03-28 | Takada Seiyaku Kk | 関節性疾患治療剤 |
AU783886B2 (en) * | 1999-06-18 | 2005-12-22 | Innovata Plc | Biologically active materials |
GB2392913B (en) * | 2002-09-11 | 2007-04-04 | Johnson & Johnson Medical Ltd | Wound dressings comprising complexes of oxidised celluloses with silver |
WO2004024197A1 (en) | 2002-09-11 | 2004-03-25 | Johnson & Johnson Medical Limited | Wound dressing materials comprising complexes of anionic polysaccharides with silver |
DK200301128A (da) * | 2003-08-05 | 2005-02-06 | Thomsen Joern Oddershede | Tilskudspræparat |
CZ304654B6 (cs) | 2012-11-27 | 2014-08-20 | Contipro Biotech S.R.O. | Nanomicelární kompozice na bázi C6-C18-acylovaného hyaluronanu, způsob přípravy C6-C18-acylovaného hyaluronanu, způsob přípravy nanomicelární kompozice a stabilizované nanomicelární kompozice a použití |
EP3988121A1 (en) | 2014-02-27 | 2022-04-27 | Synartro AB | Hyaluronan conjugates with pharmaceutically active substances, methods and compositions |
CZ2014451A3 (cs) | 2014-06-30 | 2016-01-13 | Contipro Pharma A.S. | Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití |
CZ309295B6 (cs) | 2015-03-09 | 2022-08-10 | Contipro A.S. | Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití |
CZ306479B6 (cs) | 2015-06-15 | 2017-02-08 | Contipro A.S. | Způsob síťování polysacharidů s využitím fotolabilních chránicích skupin |
CZ306662B6 (cs) | 2015-06-26 | 2017-04-26 | Contipro A.S. | Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití |
CZ308106B6 (cs) | 2016-06-27 | 2020-01-08 | Contipro A.S. | Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití |
WO2019121488A1 (en) * | 2017-12-21 | 2019-06-27 | Nicox S.A. | Nitric oxide releasing hyaluronic esters |
JP7066909B1 (ja) * | 2020-12-25 | 2022-05-13 | 参天製薬株式会社 | 高分子化合物、銀塩およびイオン性等張化剤を含有する水性点眼液 |
IT202100012737A1 (it) | 2021-05-18 | 2022-11-18 | Jointherapeutics S R L | Miscele di polisaccaridi e poliamminosaccaridi con proprietà reologiche migliorate |
IT202100013787A1 (it) | 2021-05-27 | 2022-11-27 | Farmigea Spa | Composizione per l’uso nel trattamento di affezioni oculari, quali sindrome dell’occhio secco, specialmente post-chirurgico oftalmico / a composition for use in the treatment of ocular affections, such as dry eye disease, especially after eye surgery |
IT202200004613A1 (it) | 2022-03-10 | 2023-09-10 | Cmed Aesthetics S R L | “procedimento di preparazione di prodotti sterili” |
WO2024038088A1 (en) | 2022-08-16 | 2024-02-22 | Synartro Ab | Liquid formulations |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5436388A (en) * | 1977-08-26 | 1979-03-17 | Sumitomo Electric Ind Ltd | Porous polysaccharide and its preparation |
EP0066283B1 (en) * | 1981-06-02 | 1986-09-10 | Eupan Corporation | Eustatic composition for nonspecifically facilitating and amplifying the generalized homeostatic regulation and maintenance, compensation and repair in living organisms |
CA1291034C (en) * | 1987-10-19 | 1991-10-22 | Mostafa S. Fahim | Composition for promoting epithelial regeneration |
US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
US4746504A (en) * | 1986-03-14 | 1988-05-24 | Bio-Technology General Corp. | Heavy metal salts of hyaluronic acid and their use as antimicrobial agents |
-
1995
- 1995-05-10 IT IT95PD000090A patent/IT1281877B1/it active IP Right Grant
-
1996
- 1996-05-08 EP EP96916030A patent/EP0827514B1/en not_active Expired - Lifetime
- 1996-05-08 CA CA002220682A patent/CA2220682C/en not_active Expired - Fee Related
- 1996-05-08 WO PCT/EP1996/001979 patent/WO1996035720A1/en active IP Right Grant
- 1996-05-08 AU AU58944/96A patent/AU695512B2/en not_active Ceased
- 1996-05-08 ES ES96916030T patent/ES2137694T3/es not_active Expired - Lifetime
- 1996-05-08 JP JP53376996A patent/JP4264671B2/ja not_active Expired - Fee Related
- 1996-05-08 AT AT96916030T patent/ATE183206T1/de not_active IP Right Cessation
- 1996-05-08 DE DE69603721T patent/DE69603721T2/de not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009510186A (ja) * | 2005-09-26 | 2009-03-12 | ノボザイムス バイオポリマー アクティーゼルスカブ | アリール/アルキル無水琥珀酸ヒアルロナン誘導体 |
JP2014500257A (ja) * | 2010-11-19 | 2014-01-09 | フィディア ファーマチェウティチ ソシエタ ペル アチオニ | 抗菌および創傷治癒活性を持つ組成物 |
JP2018510962A (ja) * | 2015-04-07 | 2018-04-19 | ヒャルブルー エス.アール.エル. | グリコサミノグリカンエステル、それらを調製する方法および眼科用途のための製剤におけるそれらの使用 |
Also Published As
Publication number | Publication date |
---|---|
AU695512B2 (en) | 1998-08-13 |
AU5894496A (en) | 1996-11-29 |
WO1996035720A1 (en) | 1996-11-14 |
ES2137694T3 (es) | 1999-12-16 |
EP0827514B1 (en) | 1999-08-11 |
DE69603721D1 (de) | 1999-09-16 |
CA2220682A1 (en) | 1996-11-14 |
DE69603721T2 (de) | 2000-01-13 |
JP4264671B2 (ja) | 2009-05-20 |
ATE183206T1 (de) | 1999-08-15 |
EP0827514A1 (en) | 1998-03-11 |
ITPD950090A0 (it) | 1995-05-10 |
CA2220682C (en) | 2006-10-24 |
IT1281877B1 (it) | 1998-03-03 |
ITPD950090A1 (it) | 1996-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11504668A (ja) | ヒアルロン酸との又はヒアルロン酸エステルとのコハク酸ヘミエステルの重金属塩類、それらの製造方法及びその医薬組成物 | |
US4929722A (en) | Acid decrystallization of aminopolysaccharides and derivatives thereof | |
RU2230073C2 (ru) | Способ поперечного сшивания карбоксилированных полисахаридов | |
EP0271551B1 (en) | Acid decrystallization of higly cristalline chitosan or partially deacylated chitin | |
DE69610370T3 (de) | Mit Antioxidantien gepfropfte Polysaccharide und deren Verwendungen | |
JP4417547B2 (ja) | 物理的な止血活性および塞栓活性、および吻合後の癒着形成についての予防活性を有している生体適合材料の製造におけるヒアルロン酸誘導体の使用 | |
JP2571312B2 (ja) | ヒアルロン酸会合物を含む新規組成物及びそれを調製するための方法 | |
JP5797673B2 (ja) | ヒドロカルビルスルトン化合物(a hydrocarbyl sultone compound)による化学修飾ポリアミノ糖 | |
FI94767B (fi) | Ei-terapeuttisesti käytettävät hyaluronihapon täydelliset ja osittaiset esterit | |
EP2289970B1 (fr) | Polymères biocompatibles | |
DE60113398T2 (de) | Polysaccharidester von n-derivaten der glutaminsäure | |
JP6000511B2 (ja) | 酸性多糖の酪酸−ギ酸混合エステル、ならびに肌用化粧品としてのその調製および使用 | |
US6258796B1 (en) | Water soluble lipidated arabinogalactan | |
JPH069707A (ja) | 高アセチル化率ヒアルロン酸及びその製造方法 | |
JP3282729B2 (ja) | 自己架橋ゲランガム | |
DD285606A5 (de) | Verfahren zur herstellung von selektiv o-azylierten glucosaminoglycanen | |
JP2001510502A (ja) | O−硫酸化細菌性多糖類 | |
US6017901A (en) | Heavy metal salts of succinic acid hemiesters with hyaluronic acid or hyaluronic acid esters, a process for their preparation and relative pharmaceutical compositions | |
JP2003523459A (ja) | キトサン縮合生成物、その製造及び使用 | |
WO2019082097A1 (en) | FUNCTIONALIZED HYALURONIC ACID OR A DERIVATIVE THEREOF IN THE TREATMENT OF INFLAMMATORY CONDITIONS | |
JP2015507070A (ja) | 部分的に解重合したグリコサミノグリカン銀及び金塩 | |
JP2511675B2 (ja) | ポリオキシエチレン化キチンの製造方法 | |
CN108635340A (zh) | 一种新型曲安奈德高分子药物长效缓释膜片及其制备方法 | |
JP4411847B2 (ja) | ポリウロン酸の製造方法 | |
JP2006291097A (ja) | ヒアルロン酸誘導体、およびその製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070710 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071009 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071119 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071109 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071217 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071207 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081028 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090106 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090203 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120227 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |